source
- AbbVie’s eczema antibody shows statistically significant benefit in Phase 2 trialAbbVie presented Phase 2 results for its experimental eczema treatment, an anti‑IL‑13 antibody named Zumilokibart. The study met its primary endpoints, demonstrating statistically significant impr…
- American Biotech Innovation Alliance urges Congress to prioritize US leadership in biopharmaThe American Biotech Innovation Alliance, formed in May, appeared on Capitol Hill on September 30, 2026 to address lawmakers. The group argued that maintaining U.S. dominance in biopharma requires…